NewEdge Advisors LLC Has $6.44 Million Stake in Natera, Inc. $NTRA

Key Points

• NewEdge Advisors increased its Natera stake by 335.3% in the second quarter, ending with 23,730 shares valued at approximately $6.44 million. Institutional investors and hedge funds collectively own 99.90% of Natera.
• Analysts remain broadly bullish, with Natera receiving a consensus “Moderate Buy” rating and an average price target of $330.83. Recent targets range from $340 to $435.
• Natera reported second-quarter revenue of $752.75 million, up 37.7% year over year and above estimates, while its adjusted loss of $0.47 per share beat expectations. Shares opened at $328.93, near the company’s 52-week high of $343.18.

NewEdge Advisors LLC raised its position in Natera, Inc. (NASDAQ:NTRA - Free Report) by 335.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 23,730 shares of the medical research company's stock after purchasing an additional 18,278 shares during the quarter. NewEdge Advisors LLC's holdings in Natera were worth $6,441,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. acquired a new position in Natera during the second quarter worth $2,962,770,000. K.J. Harrison & Partners Inc bought a new position in shares of Natera in the 2nd quarter valued at about $5,117,000. Abbot Financial Management Inc. acquired a new stake in shares of Natera in the second quarter valued at about $1,537,000. Eagle Health Investments LP bought a new stake in Natera during the second quarter worth about $4,302,000. Finally, Fifth Third Bancorp grew its stake in Natera by 3,373.1% in the first quarter. Fifth Third Bancorp now owns 11,253 shares of the medical research company's stock valued at $2,251,000 after purchasing an additional 10,929 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on NTRA shares. TD Cowen increased their price objective on Natera from $325.00 to $340.00 and gave the company a "buy" rating in a report on Friday, August 7th. Canaccord Genuity Group set a $375.00 price target on shares of Natera in a research note on Friday, August 7th. UBS Group lifted their price objective on shares of Natera from $290.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday, September 9th. Piper Sandler boosted their price objective on shares of Natera from $249.00 to $363.50 and gave the stock an "overweight" rating in a research note on Wednesday, August 12th. Finally, Zacks Research raised shares of Natera from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $330.83.

Insiders Place Their Bets

In other Natera news, Director Herm Rosenman sold 16,530 shares of the stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the transaction, the director directly owned 4,250 shares of the company's stock, valued at $1,062,500. This represents a 79.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Rowan Chapman sold 2,964 shares of the firm's stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $216.78, for a total transaction of $642,535.92. Following the sale, the director owned 3,124 shares of the company's stock, valued at $677,220.72. This trade represents a 48.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,206 shares of company stock worth $19,944,069 in the last 90 days. Corporate insiders own 5.05% of the company's stock.

Natera Price Performance

Shares of Natera stock opened at $328.93 on Monday. The business has a fifty day simple moving average of $297.80 and a two-hundred day simple moving average of $241.89. Natera, Inc. has a 1 year low of $157.43 and a 1 year high of $343.18. The company has a market capitalization of $47.41 billion, a price-to-earnings ratio of -241.86 and a beta of 1.54.

Natera (NASDAQ:NTRA - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. The firm had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company's quarterly revenue was up 37.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.74) earnings per share. As a group, equities analysts anticipate that Natera, Inc. will post -1.02 earnings per share for the current fiscal year.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services based on cell-free DNA and other genomic technologies. The company focuses on reproductive health, oncology and organ health, providing tests intended to support screening, diagnosis, treatment planning and disease monitoring.

Its reproductive health portfolio includes Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.